Humana’s Star Ratings Recovery Still Needs an Earnings Bridge

A better rating is the beginning of the earnings analysis

Humana’s October 9 disclosures strengthen the evidence for a recovery in its Medicare Advantage quality performance. They do not establish how much recurring profit shareholders will receive. The useful investment question is how improved ratings flow through future payments, benefit design and expenses, and how much of that improvement can endure. Treating the announcement as an automatic earnings increase would skip those intermediate steps.

In supplementary commentary, Humana reported a member-weighted Star Rating of 4.17, compared with 3.84 for the previous bonus year using its current contract and member mix. It said 95% of members were in contracts rated four stars or higher. Those are company-level measures of the distribution of members across contracts, not a statement that every plan has the same rating or that every member generates the same financial contribution.

Keep the rating year and payment year separate

CMS published the 2027 ratings on October 8, 2026. Its fact sheet says these ratings will affect 2028 Medicare Advantage quality bonus payments. The gap matters: a disclosure made this autumn is evidence about a future payment framework, rather than cash already collected in the current quarter. Investors should label those years explicitly in their research notes.

CMS also distinguishes contract counts from enrollment-weighted results. About 37% of Medicare Advantage prescription-drug contracts offered in 2027 earned at least four stars, while approximately 71% of enrollees were in such contracts. The percentages answer different questions. A large contract carries more weight in the membership measure than a small one, so an unweighted count cannot substitute for the economic exposure of an insurer’s members.

That distinction provides a useful check on comparisons with competitors. Match the population, weighting and rating year before concluding that one percentage proves superior economics. A quality score is valuable evidence, but it does not independently describe medical costs, member retention or the price of the benefits offered.

The company’s comparison is not a cash forecast

Humana’s October 9 Form 8-K says its results exceeded its Top Quartile goal, defined as Stars revenue per member per month 10% above the peer-group median. The calculation normalizes important inputs and uses September 2026 membership and contract distribution. The filing explicitly cautions that actual 2028 revenue on this measure will depend on the membership, contract mix and payment inputs prevailing then.

For an investment model, the immediate implication is to avoid multiplying a normalized comparison by an assumed future member count and calling the result reported revenue. A sensitivity exercise could be useful, but its inputs would need to be labeled assumptions. The disclosure supports a stronger quality-performance assessment without supplying a complete, realized earnings bridge.

A sound comparison therefore preserves both the standardized quality result and the uncertainties around future economics. Collapsing them into one headline number would hide the assumptions that still need to be tested.

Temporary upside and durable improvement need different treatment

Management’s supplementary remarks say it intends to manage benefits around performance approximating its Top Quartile objective. It does not expect the extra outperformance in Bonus Year 2028 to repeat in Bonus Year 2029, citing program design, member movement across contracts and other structural factors. That is an important limit on extrapolation even if the broader recovery remains intact.

Our interpretation is that a valuation case should separate a potentially temporary benefit from an improvement in the continuing business. Applying a recurring earnings multiple to every favorable item would risk overstating durability. Conversely, a temporary component does not negate genuine operational improvement. The next evidence should show which gains are retained, which support benefits or investment, and which persist as the contract mix changes.

The constructive case strengthens if subsequent disclosures connect quality improvement with sustainable margins and transparent capital allocation. It weakens if the expected benefit is absorbed without a durable improvement in returns. Neither outcome is established by the ratings announcement alone; the central task is to follow the financial conversion of a better quality result.